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The myocardial regenerative 
potential of three-dimensional 
engineered cardiac tissues 
composed of multiple human iPS 
cell-derived cardiovascular cell 
lineages
Hidetoshi Masumoto1,2,3,*, Takeichiro Nakane1,2,3,*, Joseph P. Tinney1,4, Fangping Yuan1,4, 
Fei Ye1,4, William J. Kowalski1,4, Kenji Minakata3, Ryuzo Sakata3, Jun K. Yamashita2 & 
Bradley B. Keller1,4
Human induced pluripotent stem cells (hiPSCs) are a robust source for cardiac regenerative therapy due 
to their potential to support autologous and allogeneic transplant paradigms. The in vitro generation 
of three-dimensional myocardial tissue constructs using biomaterials as an implantable hiPSC-derived 
myocardium provides a path to realize sustainable myocardial regeneration. We generated engineered 
cardiac tissues (ECTs) from three cellular compositions of cardiomyocytes (CMs), endothelial cells 
(ECs), and vascular mural cells (MCs) differentiated from hiPSCs. We then determined the impact of 
cell composition on ECT structural and functional properties. In vitro force measurement showed that 
CM+EC+MC ECTs possessed preferential electromechanical properties versus ECTs without vascular 
cells indicating that incorporation of vascular cells augmented tissue maturation and function. The 
inclusion of MCs facilitated more mature CM sarcomeric structure, preferential alignment, and activated 
multiple tissue maturation pathways. The CM+EC+MC ECTs implanted onto infarcted, immune 
tolerant rat hearts engrafted, displayed both host and graft-derived vasculature, and ameliorated 
myocardial dysfunction. Thus, a composition of CMs and multiple vascular lineages derived from hiPSCs 
and incorporated into ECTs promotes functional maturation and demonstrates myocardial replacement 
and perfusion relevant for clinical translation.
Stem cell-based cardiac regeneration is a rapidly expanding paradigm with the expectation of delivering novel 
therapeutic approaches for severe cardiac disorders resistant to current therapies1–5. The in vitro formulation of 
three-dimensional (3D) organized and implantable myocardial tissue constructs has emerged as a robust method 
to realize myocardial replacement in preclinical models6–9. The acceleration of structural and functional in vitro 
maturation, optimized in vivo survival, and functional integration of human cell-derived engineered cardiac 
tissues (ECTs) to failing recipient myocardium remain major requirements for clinical translation. While much 
of the focus has been on the incorporation of cardiomyocyte (CM) lineages into ECTs, non-myocytes including 
vascular cell lineages serve pivotal roles during myocardial development and in the generation and remodeling 
of bioengineered tissue architecture7,8,10. Engineered constructs that include these multiple lineage constructs are 
more likely to replicate the dynamic organization and function of native myocardium.
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Among the stem cell types, pluripotent stem cells [Embryonic stem cells (ESCs)/induced pluripotent stem 
cells (iPSCs)] possess great potential for cardiac regeneration due to their capacity for robust in vitro expansion 
followed by directed differentiation into most somatic cell lineages including CMs or other vascular cell types11,12. 
The generation of iPSCs by reprogramming somatic cells with genes regulating pluripotency may resolve the 
ethical and immunogenic issues associated with the clinical application of ESCs.
We have investigated multiple compositions of ECTs generated from immature chick or rat fetal/neona-
tal heart cells13–15 to validate preclinical cardiac repair paradigms. Furthermore, we also have reported that 
co-existence of CMs and vascular cell lineages within mouse ESC-engineered cell sheet structure augmented cell 
sheet function10, and the transplantation of cell sheets engineered from human iPSC (hiPSC)-derived multiple 
cardiac lineages (cardiac tissue sheets) brought functional recovery and myocardial regeneration on a rat myo-
cardial infarction (MI) model8. We hypothesized that ECTs composed by human iPSC (hiPSC)-derived cardio-
vascular cells hold promise to realize an ideal 3D structure for clinical application. In the present study, we utilize 
a strategy that identified an optimal composition of multiple cardiovascular cell populations derived from hiPSCs 
to generate ECT grafts with improved tissue maturation and with excellent post-implantation survival, perfusion, 
and contribution to functional recovery relevant to clinical application.
Results
We optimized our previously reported hiPSC cardiovascular cell induction protocol to induce CMs along with 
endothelial cells (ECs)8 which resulted in the efficient induction of cardiac troponin-T (cTnT)+ CMs (61.8 ± 8.0% 
of total cells) and vascular endothelial (VE)-cadherin (CD144)+ ECs (19.4 ± 9.1%) with little co-induction of 
platelet-derived growth factor receptor beta (PDGFRβ ; CD140b)+ vascular mural cells (MCs) (1.7 ± 2.0%) by day 
15 (d15; n = 26) (Supplementary Fig. 1; CM+ EC protocol). Wnt3a treatment significantly increased CM and EC 
induction and decreased MC induction (Supplementary Fig. 2). We generated ECTs composed of cells harvested 
on d15, collagen I and Matrigel. ECTs displayed spontaneous beating after 3 to 4 days in culture (hiPSC-ECT with 
CMs and ECs; CM+ EC) (Fig. 1a, Supplementary Fig. 3a and Supplementary Video 1). Human iPSC-derived 
ECTs underwent rapid gel compaction which facilitated continued nutrient delivery during construct matura-
tion16 (Supplementary Fig. 4).
To explore the potential for vascular mural cells (MCs) to further accelerate ECT formation and matura-
tion, we expanded the vascular lineage composition and revised our ECT composition to include MCs which 
are abundant in maturing and adult muscles, including the heart, and facilitate tissue growth, physiology17–19 
Figure 1. Electromechanical properties of hiPSC-ECTs. (a) Schematic diagrams for composition of 3 types 
of ECTs (upper) containing cardiomyocytes (CM), endothelial cells (EC), and/or mural cells (MC) and the 
proportions of each cell type used to generate ECTs (lower). Groups sizes were n = 8 (CM+ EC), n = 7 (CM+ 
MC), and n = 12 (CM+ EC+ MC). (b–d) Results of contractile force measurements [n = 8 (CM+ EC), n = 7 
(CM+ MC) and n = 12 (CM+ EC+ MC)]. (b) Maximum capture rate (left), relaxation time (center) and 
excitation threshold (right) (c) Transition of active force according to the increase of pacing frequency (from 
2Hz to 3.5Hz). (d) Young’s modulus. NS, not significant; * P < 0.05, * * P < 0.01, * * * P < 0.001.
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and structural integrity7,8,10. We employed 2 additional hiPSC differentiation protocols. The primary MC pro-
tocol is a modification of a previously reported method20,21 that preferentially induces MCs without CMs or 
ECs (Supplementary Fig. 1) and resulted in 74.4 ± 8.4% PDGFRβ + MCs (n = 42). A secondary CM+ MC proto-
col is modified from our previous report22 to preferentially induce CMs and MCs without ECs (Supplementary 
Fig. 1). We combined cells from these 3 induction protocols to adjust final MC ratios as 5 to 25% of total cells, 
and generated 2 additional ECT classes: ECTs with CMs, ECs and MCs (CM+ EC+ MC), and ECTs with CMs 
and MCs but without ECs (CM+ MC) (Fig. 1a and Supplementary Fig. 3a). The cellular components of TRA-1-
60-positive undifferentiated hiPSCs within cell mixtures used for each ECT class were 4.1 ± 3.7% in CM+ EC 
(n = 17), 5.9 ± 0.9% in CM+ MC (n = 7) and 5.9 ± 2.8% in CM+ EC+ MC (n = 33), respectively.
We assessed ECT electromechanical properties and functional maturation using a custom intact muscle test 
system (Supplementary Fig. 3b,c). Active force generation trended higher in the CM+ EC ECT group at 2Hz/5V 
pacing, consistent with a higher CM ratio in CM+ EC (63.1 ± 7.0%) compared to other 2 types (CM+ EC+ MC: 
48.3 ± 6.8%, P < 0.001; CM+ MC: 43.6 ± 4.7%, P < 0.0001) (Supplementary Fig. 5a). Interestingly, there was 
no direct correlation between CM ratio and active force (P = 0.248), highlighting the important contributions 
of non-CM subpopulations (Supplementary Fig. 5b). The highest active stress generated by hiPSC-ECTs was 
1.49 mN/mm2 (average of 0.62 mN/mm2), comparable to human pediatric myocardium (1–1.5 mN/mm2), but 
less than adult myocardium (15–30 mN/mm2)23. Next, we found that the paced maximum capture rate (MCR) 
was significantly higher in CM+ EC+ MC (consistently greater than 240 bpm) compared to other ECT types 
(Fig. 1b). We also found that relaxation time (RT)24 (Supplementary Fig. 6b) was shortest in CM+ EC+ MC, 
which would facilitate higher MCR (Fig. 1b). In CM+ EC+ MC, there was a positive correlation between MC 
ratio and MCR (R2 = 0.433, P < 0.05), and negative correlation between MC ratio and RT (R2 = 0.669, P < 0.01) 
(Supplementary Fig. 6) indicating ratio-dependent contribution of MCs to MCR. We also noted that the excita-
tion threshold (ET) required to induce ECT contraction was significantly lower in CM+ EC+ MC compared to 
CM+ MC, and lower but not significantly different than CM+ EC (Fig. 1b). We next assessed active force pro-
duction at frequencies higher than 2 Hz (120 bpm). Approximately 75% of active force was maintained at 3.5 Hz 
(210 bpm) in CM+ EC+ MC, whereas active force in CM+ EC or CM+ MC at 3.5 Hz decreased to approximately 
40% of baseline 2 Hz-force (Fig. 1c). These results indicate that ECTs incorporating both MCs and ECs have the 
potential for coupling to higher in vivo recipient beat rates after implantation without decreasing the active force 
production. Thus, ECTs composed of CM+ EC+ MC demonstrated excellent electromechanical properties com-
pared to other ECT classes.
We further examined whether tissue stiffness, an important feature of tissue maturation and function, could 
be altered by vascular cell incorporation. In the native heart, passive force is affected by tissue length accord-
ing to Hooke’s law (law of elasticity)25 and tissue elongation increases active force according to Frank-Starling 
mechanisms26. We measured and plotted passive stresses at increasing lengths (up to 25%) from slack length 
and found that the passive stress-length relationship was consistent with Hooke’s law for all ECT compositions 
(Supplementary Fig. 7a) (average R2 value: 0.922 in CM+ EC, 0.885 in CM+ MC, 0.882 in CM+ EC+ MC)25. We 
found that Young’s modulus were higher in ECTs with MCs (CM+ MC and CM+ EC+ MC) compared to those 
without MCs (CM+ EC), indicating that MCs contribute to produce higher tissue stiffness (Fig. 1d). The highest 
Young’s modulus in CM+ EC+ MC reached over 17 kPa (average of 8.8kPa) which is comparable to reported 
normal cardiac muscle tissue stiffness (10–15 kPa)27. Active stress-length relationships for all ECT compositions 
were consistent with a positive Frank-Starling relationship similar to the native heart (average R2 value: 0.972 in 
CM+ EC, 0.961 in CM+ MC, 0.973 in CM+ EC+ MC) indicating that ECTs recapitulate a fundamental property 
of native cardiac muscle (Supplementary Fig. 7b)25. We examined the effect of MCs on ECT remodeling. Gel com-
paction rate was higher in ECTs with MCs compared to those without MCs (Supplementary Fig. 4).
To assess Ca2+ channel and sarcoplasmic reticulum (SR) maturation of hiPSC-derived CMs included in each 
class of ECTs, we performed force measurement analyses under various Ca2+ concentrations and administra-
tion of caffeine. There was a tendency (not significant) of immature SR pattern in ECTs without ECs (CM+ 
MC) compared to ECTs with ECs (CM+EC and CM+EC+MC) in response to external Ca2+ concentration 
(Supplementary Fig. 8a)28 or caffeine (5 mM) to increase SR ryanodine channel open state (Supplementary Fig. 
8b)16. However, the Ca2+ EC50 (half maximal effective concentration) values of our ECTs (Supplementary Fig. 8a) 
(around 1 mM) were much lower than those reported as those for adult human muscle strips (around 3.0 mM)28, 
consistent with a greater reliance of immature myocardium on sarcolemmal Ca2+ influx rather than Ca2+ release 
from SR for contraction, similar to reported human pluripotent stem cell-derived CMs16. Thus, although there are 
obvious advantages to the CM+EC+MC ECT composition relevant to electromechanical function, we noted no 
clear preferential effect on the maturation of individual CM Ca2+ channel and SR function indicating co-existence 
of vascular cells within 3D tissue structure compensated the immaturity of individual CMs.
Next, we investigated structural mechanisms that could account for the functional advantages of incorporat-
ing vascular cells into ECTs. We analyzed myofiber alignment and found that ECTs containing MCs had increased 
alignment as quantified by increased concentration parameter (κ ) (Fig. 2a) and reduced circular standard devia-
tion (Supplementary Fig. 9) consistent with increased CM alignment parallel to the ECT long axis. As expected, 
tissue maturation within 3D ECT constructs was associated with greater cellular alignment compared to 2D 
culture. We further noted that sarcomeric structural maturation in individual CM was more pronounced in CMs 
within ECTs containing both MCs and ECs (CM+ EC+ MC). ECTs with both ECs and MCs demonstrated par-
allel myofibers with clear Z-line, I-band and A-band along with mitochondria localized between myofibers, a 
representative feature of mature myocytes not consistently present in other ECT classes (Fig. 2b). Sarcomeric 
structural maturation was more prominent following longer in vitro culture up to 8 weeks in ECTs including ECs 
and MCs (Fig. 2c). Thus, we noted that vascular incorporation was associated with in vitro tissue remodeling 
that improves biophysical properties including better cellular alignment and increased structural maturation of 
individual CM. We further examined whether vascular cell incorporation altered gene expression profiling in 
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ECTs. RNA sequencing analysis for ECTs after 14 days of in vitro culture revealed the inclusion of MCs resulted in 
the activation of multiple gene ontology pathways consistent with accelerated tissue maturation (Fig. 2d), which 
might have contributed to observed increased ECT structural and functional maturation.
Finally, considering the results that ECTs including all 3 cardiovascular lineages (CMs/ECs/MCs) exhib-
ited highest tissue function in vitro, we examined the in vivo potential of CM+ EC+ MC hiPSC-ECTs to con-
tribute to functional recovery and myocardial regeneration in an immune tolerant rat MI model (Figs 3–5, 
and Supplementary Videos 2,3). All implanted (n = 6) and sham operated rats (n = 5) survived the 4-week 
post-implant observation period with no tumor formation. We noted that implanted hiPSC-ECTs including vas-
cular cells ameliorated left ventricular (LV) dysfunction following MI (Fig. 3c,d and Supplementary Video 3). 
Implanted ECTs engrafted at infarction sites and produced human nucleic antigen (HNA)+, thick (> 800 μ m) 
regenerated myocardium at 4 weeks after implantation (Figs 4a and 5a). All implanted rats exhibited ECT 
engraftment (n = 6) and the engrafted area reached 42.0 ± 16.9% of the infarcted area (ranged from 24.6% to 
67.4%) (Supplementary Fig. 10). Regenerated myocardium with obvious sarcomeric structures (Fig. 4b) occu-
pied greater than half the thickness of infarcted heart wall. We confirmed abundant von Willebrand factor 
(vWF)+ vascular luminal structures around the regenerated myocardium and penetrating to the central area 
of the neo-myocardium resulting in blood supply to the whole tissue (Fig. 4c). The majority of these vascular 
structures contained host-derived, (HNA− and vWF+) vascular cells, consistent with host-derived vascular inva-
sion of the implanted ECT through possible angiogenic stimuli8, though some vascular structures represented 
Figure 2. Structural and functional maturation of hiPSC-ECTs including vascular cells. (a) Representative 
alignment analysis using cTnT-stained images after 2-dimensional (2D) and 3-dimensional (3D) culture 
(left) (see Supplementary Fig. 8 for whole images of nuclei and myofiber) for 3 types of ECTs containing 
cardiomyocytes (CM), endothelial cells (EC), and/or mural cells (MC). Calculated concentration parameter (κ ), 
an index of that is related to myofiber alignment, for each culture condition (right) [n = 3 (2D) and 5 (each 3D)]. 
cTnT, cardiac troponin T; Deg, degree. (b) Representative Transmission electron microscopic images for each 
type of ECT cultured 4 weeks. Lower panels indicate higher magnification images. Arrows indicate myofibers. 
N, nucleus; Mt, mitochondria; I, I-band; A, A-band; Z, Z-line. (c) Representative cTnT immunostaining of 
ECTs (CM+EC+MC) cultured in vitro for different periods. Inset shows single CM image showing sarcomeric 
structure. 2/4/8 wk, cultured in vitro for 2, 4, or 8 weeks, respectively. DAPI, 4, 6 diamidino-2-phenylindole. 
(d) Representative gene processes significantly regulated by the addition of mural cells (CM+ EC+ MC versus 
CM+ EC) in hiPSC-ECTs. Gene ontology processes (left), and pathways and process networks (right). Scale bars 
represent significance expressed as the –log p Value and values within each bar represent the number of altered 
genes and total genes in each network. Scale bars: 20 μ m in (a), (c) (main panels), 10 μ m in (c) (inset), 2 μ m in 
(b) (upper panels) and 1 μ m in (b) (lower panels). * * P < 0.01, * * * P < 0.001.
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chimeric composites of both host and graft-derived vasculature. We further confirmed functioning vascular con-
nection between the recipient myocardium and implanted ECT grafts using host vascular injection of fluorescent 
dye-conjugated lectin to identify perfused vessels within engrafted tissue (Fig. 5a). We also identified evidence for 
Connexin 43 expression within regenerated myocardium at 4 weeks after ECT implantation indicating existence 
of gap junction between CMs (Fig. 5b).
Discussion
In the present study, we successfully generated a novel 3D ECT composition of hiPSC-derived cardiomyocytes, 
vascular endothelial cells, and mural cells that displays excellent in vitro structural maturation and electrome-
chanical performance, is capable of in vivo survival, remodeling, and perfusion post-implantation, and contrib-
utes to myocardial repair and recovery. The CM+ EC+ MC ECT composition produced functional myocardium 
with structural and performance characteristics favorably suited for the altered physiology of the failing heart 
such as increased heart rate as a compensatory mechanism of decreased cardiac output or augmented adrenergic 
activity (compensatory tachycardia)29, and lower depolarization threshold consistent with the decreased total 
electrical voltage of a failing heart30.
As has previously been noted with the addition of fibroblasts into ECTs25, our approach of complementing 
the CM population in ECTs with vascular constituents (EC and MC) more closely resembles native myocardium 
and likely facilitates the maturation and the structural and vascular coupling of implanted ECTs to the recipient 
myocardium. Even though it remains likely that in vitro matured ECT remain electromechanically immature 
compared to native heart tissues, the co-existence of vascular constituents with CMs altered ECT biomechanical 
properties, including increased structural maturation and CM alignment with ECT myofibers. The functional 
immaturity of hiPSC-derived isolated CM and derived tissues is well recognized16,31, and the incorporation of 
non-CM lineages to generate more representative myocardial constructs may be one solution to this barrier to 
translation.
The role of non-myocytes in facilitating the in vitro maturation, in vivo survival, and adaptation of ECTs 
remains highly intriguing. Recognizing the complexity of quantifying gene expression patterns in this engineered 
construct, we noted that the addition of MCs increased transcript expression in numerous regulatory pathways 
associated with myocardial maturation (Fig. 2d). While, validation of the roles of individual transcripts and path-
ways was beyond the scope of the current study, additional experiments can explore the roles of unique cellular 
constituents and pathways in ECT structural and functional maturation, as well as in vivo survival and adaptation.
Even though the extent of functional recovery after implantation of hiPSC-derived ECTs to a rat 
sub-acute 1-week MI model was lower than that of our previous report of hiPSC-derived cardiac tissue sheet 
Figure 3. Cardiac implantation of hiPSC-ECTs on the infarcted rat heart and functional recovery. 
(a) Schematic timeline of rat surgery. MI, myocardial infarction; Echo, echocardiogram; IHC, 
immunohistochemistry. (b) Three hiPSC-ECTs bundled and prepared for implantation (left). ECTs implanted 
onto the heart surface at infarction site (right) (arrow). (c,d) Results of echocardiogram. (c) Representative 
M-mode images for sham-operated (left) and ECT-implanted (right) rats 4 weeks after surgery. Tx, ECT-
implanted. (d) Results of B-mode echocardiogram [n = 6 (Tx) and 5 (sham)]. Cardiac output (mL/min) (left 
upper), stroke volume (fold increase to PreTx) (right upper), left ventricular end diastolic area (LVAd; mm2) 
(left lower) and ejection fraction (fold increase to PreTx) (right lower). PreTx, before treatment; Tx2w/4w, 2/4 
weeks after treatment. * P < 0.05. * * P < 0.01. N.S., Not significant.
www.nature.com/scientificreports/
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transplantation8, the implantation of ECTs showed higher efficiency of engraftment in that all 6 rats demonstrated 
ECT engraftment. Cell sheets potentially cover larger area of injured heart than that of ECTs which might lead to 
higher functional recovery especially for a pathology which might be more amended by paracrine factors, such as 
sub-acute MI. For the treatment of more severe pathologies resistant to indirect paracrine effects such as chronic 
disorders with extensive fibrosis, thicker organized 3D construct like ECTs as shown in the present study, or 
stacked cell sheets using gelatin hydrogel microspheres32 might be effective because of higher potential of engraft-
ment which may reconstruct functioning myocardium. Further work is required to investigate the contribution 
of indirect paracrine factors and direct mechanical ECT support to the functional recovery after hiPSC-ECT 
implantation.
In the present study, we did not prepare each cardiovascular cell population using a cell sorter to avoid sub-
stantial cell loss. Our strategy was to blend multiple cell compositions with known lineage distributions to achieve 
the desired final lineage distribution. We successfully controlled cellular components using several non-sorting 
differentiation protocols by simply changing reagents and culture media during the differentiation culture to 
yield large number of cells available for ECT formation. This approach minimizes cell loss and avoids specimen 
contamination, two key issues relevant in the transition to large-animal experiments and clinical trials.
In addition to defining the therapeutic effects of hiPSC-ECTs, we need to continue to validate the safety of 
this therapeutic modality before conducting clinical trials33,34. All implanted rats survived the 4-week observa-
tion period without accidental death suggesting no lethal arrhythmic events occurred following ECT implan-
tation onto vulnerable myocardium. As described in our previous report using hiPSC-derived cell sheet8, we 
need further assessment for the proarrhythmic potential of the iPSC-ECT implantation including investigation 
of the electrical and functional integration between the engrafted and host tissues whether the graft could work 
as native host tissue in vivo using larger animal models with similar intrinsic beating rates to the human hearts 
Figure 4. Myocardial regeneration and post-implantation in vivo reorganization of hiPSC-ECTs. (a–c) 
Left ventricular (LV) histology 4 weeks after implantation of hiPSC-ECTs (including 5% MCs). (a) Masson’s 
trichrome staining (left). Red dotted line indicates engrafted area. cTnT and HNA (human cell marker) double 
immunostaining (right). Arrows indicate engrafted myocardium. White dotted lines indicate LV border. LV, left 
ventricle; HNA, human nucleic antigen. (b) Higher magnification of cTnT and HNA double immunostaining 
showing sarcomeric structure. (c) vWF (endothelial cell marker) and HNA double immunostaining. (i) Lower 
magnification image. White arrows indicate promoted capillary formation around grafted tissue. Orange arrows 
indicate penetrating vasculature. White dotted line indicates vasculature in the center of grafted tissue. (ii) and 
(iii) Higher magnification images. (ii) Prominent host-derived (HNA−) vascular formation around regenerated 
myocardium. (iii) chimeric vasculature composed of both host (HNA−; orange arrow) and graft (HNA+; white 
arrows) vascular cells. vWF, von Willebrand factor. Scale bars: 500 μ m in (a), 200 μ m in (c) (i), 50 μ m in (c) (ii), 
20 μ m in (c) (iii), and 10 μ m in (b).
www.nature.com/scientificreports/
7Scientific RepoRts | 6:29933 | DOI: 10.1038/srep29933
and hiPSC-derived ECTs. We also need to determine the potential for implanted hiPSC-ECTs to trigger tumor 
formation through longer-term studies as well as explore the generation of hiPSC-ECTs from iPSCs established 
with episomal plasmid vectors considered to minimize genomic integration35.
In conclusion, we provide new evidence that a more complex composition of hiPSC-derived cardiac cells 
(CM+ EC+ MC) incorporated into implantable bioengineered 3D ECTs shows favorable structural and functional 
features relevant to future clinical translation. While the optimization of hiPSC-derived CM maturation remains 
under intense investigation36, multiple lineage composition ECTs hold promise to generate hiPSC-derived cardiac 
tissues optimized for the failing in situ human myocardium. Further refinements in hiPSC-ECT compositions are 
likely to occur during large animal preclinical trials followed by Phase I-II clinical trials.
Methods
Detailed methods are described in Supplementary Methods.
Human iPSC Culture and Differentiation. Human iPSCs [4-factor (Oct3/4, Sox2, Klf4 and c-Myc) line: 
201B6, previously described in detail8,12,22 were used for this study. In brief, iPSCs were expanded and maintained 
on thin-coat matrigel (growth factor reduced, 1:60 dilution; BD Biosciences, San Jose, CA) in mouse embryonic 
fibroblast conditioned medium (MEF-CM) supplemented with 4 ng/mL human basic fibroblast growth factor 
(hbFGF; WAKO, Osaka, Japan). Cells were passaged as small clusters every 4–6 days using CTK solution [0.1% 
collagenase IV, 0.25% Trypsin, 20% knockout serum replacement (KSR), and 1 mmol/L CaCl2 in phosphate buff-
ered saline (PBS)].
Cardiovascular (CV) cell differentiation was induced as previously reported8,22 with modifications, as shown 
in Supplementary Fig. 1. Cells were detached following a 3 to 7 min incubation with Versene (0.48 mmol/L EDTA 
solution; Life Technologies, Carlsbad, CA) and seeded onto matrigel-coated plates at a density of 1,000 cells/mm2 
in MEF-CM with 4 ng/mL hbFGF for 2 to 3 days before induction. Cells were covered with matrigel (1:60 dilu-
tion) on the day before induction. To induce CV cell population, we replaced MEF-CM with RPMI+ B27 medium 
(RPMI1640; Life Technologies, 2 mmol/L L-glutamine; Life Technologies, 1× B27 supplement without insulin; 
Life Technologies) supplemented with 100 ng/mL of Activin A (R&D, Minneapolis, MN) and Wnt3a (R&D) for 
24 hours (differentiation day 0; d0), followed by 10 ng/mL human bone morphogenetic protein 4 (BMP4; R&D) 
and 10 ng/mL hbFGF (d1) for 2 or 4 days without culture medium change. Wnt3a was used at a concentration of 
100 ng/mL in all experiments unless stated otherwise. For induction of CM and EC (CM+ EC protocol): The cul-
ture medium was replaced on d5 with RPMI+ B27 supplemented with 50 ng/mL of VEGF165 (Miltenyi, Bergisch 
Figure 5. Functional coupling of implanted hiPSC-ECTs. (a) cTnT immunostaining for lectin (represents 
perfused vasculature)-perfused rat heart 4 weeks after implantation of hiPSC-ECTs (including 16% MCs). 
(i) Lower magnification image. (ii) and (iii) Higher magnification images. Perfused vasculature among (ii) 
and at central area (iii) of regenerated myocardium (arrows). (b) Cx43 (Connexin 43) and cTnT double 
immunostaining for regenerated myocardium. Scale bars: 1mm in (a) (i), 100 μ m in (a) (ii, iii), 20 μ m in (b) 
(main panel), and 10 μ m in (b) (inset).
www.nature.com/scientificreports/
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Gladbach, Germany), and culture medium was refreshed every other day. Beating cells appeared at d11 to d13. 
For induction of CM and MC (CM+ MC protocol): The culture medium was replaced on d5. We used RPMI+ 
B27 supplement with insulin (Life Technologies) and 100 ng/mL of Dkk1 (R&D) on d5 to 7 and refreshed culture 
medium every other day with RPMI+ B27 supplement with insulin. For induction of MC (MC protocol): The 
culture medium was replaced on d3 with RPMI+ 10% FBS medium [RPMI1640, 2 mmol/L L-glutamine, 10% fetal 
bovine serum (FBS)], and culture medium was refreshed every other day.
Human iPS Cell-Derived Engineered Cardiac Tissue (hiPSC-ECT) Formation. We combined 
hiPSC-derived CV cells from 3 protocols (CM+ EC protocol, CM+ MC protocol and MC protocol) (Fig. 1) to 
generate the 3 types of ECTs containing the distribution of cardiomyocytes (CM), endothelial cells (EC), and/or 
mural cells (MC) shown in Fig. 1a. Cells at differentiation (d15) were dissociated by incubation with Accumax 
(Innovative Cell Technologies, San Diego, CA). Collected cells (approximately 3.0 × 106 cells/ECT) were mixed 
with acid-soluble rat-tail collagen type I (Sigma) and matrix factors (Matrigel; BD Biosciences) similar to our pre-
viously published methods13,14. Cell/matrix mixture was performed as follows. (1) Cells were suspended within 
a culture medium (high glucose-modified Dulbecco’s essential medium; Life Technologies) containing 20% fetal 
bovine serum (Life Technologies). (2) Acid-soluble collagen type I solution (pH 3) was neutralized with alkali 
buffer (0.2 M NaHCO3, 0.2 M HEPES, and 0.1 M NaOH) on ice. (3) Matrigel (15% of total volume) was added 
to the neutralized collagen solution. (4) Cell suspension and matrix solution were mixed with a final collagen 
type I concentration of 0.67 mg/mL. Cylindrical hiPSC-ECTs were constructed using a collagen type I-coated 
silicone membrane 6-well culture plate (TissueTrain; Flexcell International, Hillsborough, FL) and FX-5000TT 
system (Flexcell International). Briefly, the center of the silicone membrane of a TissueTrain culture plate was 
deformed by vacuum pressure to form a 20-mm-length × 2-mm-width trough using a cylindrical loading post 
(FX-5000TT). Approximately 200  μ L of cell/matrix mixture was poured into the trough and incubated for 
120 min in a standard CO2 incubator (37 °C, 5% CO2) to form a cylindrical construct. Both ends of the construct 
were held by nylon mesh anchors attached to the TissueTrain culture plate. Once the tissue gelled, the culture 
plate was filled with pre-culture medium [PM; alpha minimum essential medium (αMEM; Life Technologies) 
supplemented with 10% FBS, 5 × 10−5 M 2-mercaptoethanol (Sigma) and 100 U/mL Penicillin-Streptomycin (Life 
Technologies)]. Constructed hiPSC-ECTs were cultured for > 14 days with medium change every other day.
Contractile Force Measurements. As previously described for chick and rat ECTs13,14, we excised a cen-
tral 10 mm to 15 mm length ECT segment and preserved the specimen in cold (25 °C) Tyrode’s solution contain-
ing (in mmol/L) 119.8 NaCl, 5.4 KCl, 2.5 CaCl2, 1.05 MgCl2, 22.6 NaHCO3, 0.42 NaH2PO4, 0.05 Na2EDTA, 0.28 
ascorbic acid, 5.0 glucose, and 30 2,3-butanedione monoxime (BDM) gassed with 95% O2 and 5% CO2. One 
end of the ECT was gently attached to a force transducer (model 403A, Aurora Scientific, Ontario, Canada) and 
the other end to a high-speed length controller (model 322C, Aurora Scientific) mounted on a micromanipu-
lator. Attachments were made using 10–0 nylon threads. The perfusion chamber containing the construct was 
then filled with BDM-free warmed Tyrode’s solution (37 °C, 1 ml total volume). During a 30 minute equilibration 
period the construct was field-stimulated (2 Hz/5V) (Supplementary Fig. 2b and C) and then the segment length 
of the tissue was gradually increased until total force reached maximum (Lmax) and then used Lmax during all 
subsequent force measurements. The external diameters of the tissue at each stretch increment were recorded 
using a microscope camera (model MU1000, AmScope, Irvine, CA), and the cross-sectional area (CSA, mm2) 
was calculated by assuming circular geometry. We determined passive and active force and relaxation time24 (time 
for 90% decrease of maximum) during pacing from 1 Hz to the paced maximum capture rate in pacing incre-
ments of 0.5 Hz. We then calculated minimum excitation threshold (ET) during 2Hz pacing. Stress values (active 
and passive stress; mN/mm2) were calculated by force values divided by the CSA of each specimen. Young’s mod-
uli were calculated from plots of strain and passive stress.
Animal Model Preparation and ECT Implantation. All animal surgeries were performed in accord-
ance with protocols approved by the University of Louisville and the Guide for the Care and Use of Laboratory 
Animals prepared by the Institute for Laboratory Animal Research, USA (8th ed., 2011). Male athymic nude 
rats (NTac:NIH-Foxn1rnu, Taconic Biosciences, Hudson, NY) weighing 300–360 g were used as recipients for 
hiPSC-ECT transplantation. Myocardial infarction (MI) model rats were created by permanent left anterior 
descending artery ligation using a 7–0 silk suture as previously described8. Isoflurane (3–5%) inhalation was used 
for general anesthesia, and subcutaneous injection of Buprenorphine (0.5 mg/kg, twice a day, 3 days including 
operation day) was used for analgesia. ECT implantation was performed 1 week after MI induction during the 
“sub-acute phase” of MI. A total of 11 rats were randomly divided into two groups: rats implanted with ECTs 
(Tx group; n = 6) and sham-operated rats (sham group; n = 5). As previously described13, the LV anterior wall was 
exposed through left thoracotomy. Using 7–0 silk sutures, the anterior infarcted myocardium was covered with 
3 ECT constructs along the LV circumferential direction (Fig. 3b and Supplementary Video 2). The pericardium 
was removed and ECTs were implanted onto the epicardium. For the sham-operated group, a thoracotomy was 
performed 1 week after coronary ligation; however, no ECT implantation was performed.
Cardiomyocyte Alignment and Distribution Analysis. We compared CM alignment among the 3 ECT 
groups based on the cTnT immunostained images. Five 40× images, sampled from 3 to 5 constructs, were used 
per ECT group. In addition, we compared alignment to 2-dimensional (2D) cultured CM. Local CM orientation 
was computed from the image gradient37 and we computed the concentration parameter (κ) for the associated 
von Mises distribution as a measure of alignment. A larger κ value indicates that CM orientation is more concen-
trated along a single direction38. Analysis was carried out in Matlab39 (MathWorks, Natick, MA).
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Next-generation RNA sequencing. Next-generation RNA sequencing (RNA-seq) was performed at 
University of Louisville Center for Genetics and Molecular Medicine on the Illumina NextSeq 500 (Illumina, San 
Diego, CA) using NextSeq500 High Output Kits (75 cycles, Cat# FC-404-1005). Libraries were prepared using 
True Seq Stranded Total RNA LT Sample Prep Kit-Set B (Cat# RS-122-2302) with Ribo-Zero Gold (Illumina)40. 
Quality was checked on an Agilent Bioanalyzer using Agilent DNA 1000 Kits. The final sample fragment sizes 
were approximately 260 bp. Sequencing library quantitation was done by qPCR using KAPA Library Quantitation 
Kit for Illumina Platforms before pooling equal amounts of libraries.
The samples were then divided into 36 fastq single-end raw sequencing files representing three ECT con-
ditions: CM+ EC, CM+ EC+ MC, and CM+ MC. Each of four single-end raw .fastq files for each replicate was 
concatenated into one single-end .fastq file using the Unix cat command resulting in 9 single .fastq files represent-
ing 3 conditions with 3 biological replicates. Quality control of these raw sequencing data was performed using 
FastQC (version 0.10.1). Base trimming of these raw data was performed using Trimmomatic (version 0.27) when 
the average quality within a window of 3 based fell below a phred score of 20. The trimmed sequences were then 
directly aligned to the human hg19 reference genome assembly using tophat2 (version 2.0.13). Aligned RNA-seq 
reads were assembled according to the hg19.gtf annotation file using cufflinks (version 2.2.1) and the differentially 
expressed genes (DEGs) were identified for pairwise comparison using the tuxedo suite of programs in cufflinks 
and cuffdiff (version 2.2.1). DEGs at each time point with a p-value cutoff of 0.01 were used for further analysis of 
enriched Gene Ontology Biological Processes (GO:BP)41. Data were uploaded to MetaCoreTM for enrichment 
analysis (GeneGo, Thomson Reuters, New York, NY) and analyzed using an enrichment settings threshold of 1.5, 
P < 0.01.
Statistics. The data were processed using JMP software for Windows (version10.0.2, SAS Institute Inc., Cary, 
NC). Comparisons between two groups were made with the unpaired t-test. Comparisons between > 2 groups 
were made with one-way or two-way repeated analysis of variance (ANOVA) followed by Tukey’s test as post 
hoc. Single regression analyses were performed to evaluate correlation between 2 values. Values are shown as 
mean ± SD. P values < 0.05 were considered significant.
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